Compare Nuvalent Inc (NUVL) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Consumer Discretionary Select Sector SPDR Fund trades at $114.56. The key difference: Nuvalent Inc is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| NUVL | XLY | |
|---|---|---|
Market Cap | $9.81B | — |
Sector | Technology | — |
52-Week High | $123.96 | $124.52 |
52-Week Low | $72.16 | $105.64 |
Enterprise Value | $8.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
XLY trades at $114.61, down 0.72% on the day, with technical indicators showing a bearish trend as the price approaches key support levels. The ETF faces headwinds from consumer sentiment concerns but maintains 100% analyst buy ratings. Recent news highlights XLY's strong track record in consumer discretionary exposure despite inflationary pressures affecting the sector.
The outlook remains cautiously optimistic with analyst support, though technical weakness and consumer spending risks require monitoring. Investment opportunity lies in potential sector recovery, while risks include persistent inflation and declining consumer confidence affecting discretionary spending patterns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
